Breaking News Instant updates and real-time market news.

BA

Boeing

$337.45

6.33 (1.91%)

, TMO

Thermo Fisher

$280.89

-2.56 (-0.90%)

09:00
10/23/19
10/23
09:00
10/23/19
09:00

Fly Intel: Pre-market Movers

UP AFTER EARNINGS: Boeing (BA), up 1%... Thermo Fisher (TMO), up 3%... Boston Scientific (BSX), up 7%... Invesco (IVZ), up 3%. ALSO HIGHER: Teekay Tankers (TNK), up 2% after Jefferies analyst Randy Giveans upgraded shares to Buy from Hold with a price target of $2.50, up from $1.50. The analyst increased his price targets for all tanker companies saying asset values are starting to reflect the "massive increases" in charter rates. DOWN AFTER EARNINGS: Eli Lilly (LLY), down 3%... iRobot (IRBT), down 15%... Texas Instruments (TXN), down 8%... Resideo (REZI), down 41%. ALSO LOWER: ServiceNow (NOW), down 7% after announcing CEO John Donahoe will step down from the company to become president and CEO of Nike (NKE) in January 2020. He will be replaced by Bill McDermott... MacroGenics (MGNX), down 6% after announcing results from the second pre-specified interim overall survival analysis for the Phase 3 SOPHIA study of margetuximab in patients with HER2-positive metastatic breast cancer who have previously been treated with anti-HER2-targeted therapies.

BA

Boeing

$337.45

6.33 (1.91%)

TMO

Thermo Fisher

$280.89

-2.56 (-0.90%)

BSX

Boston Scientific

$38.21

-0.45 (-1.16%)

IVZ

Invesco

$16.03

-0.115 (-0.71%)

LLY

Eli Lilly

$110.00

2.06 (1.91%)

IRBT

iRobot

$53.88

-1.82 (-3.27%)

TXN

Texas Instruments

$128.61

-2.32 (-1.77%)

TNK

Teekay Tankers

$1.99

0.08 (4.19%)

REZI

Resideo

$15.17

0.03 (0.20%)

NOW

ServiceNow

$228.26

-12.315 (-5.12%)

MGNX

MacroGenics

$11.04

-0.34 (-2.99%)

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 28

    Oct

  • 06

    Nov

  • 13

    Nov

  • 13

    Nov

  • 02

    Dec

  • 07

    Dec

  • 09

    Dec

  • 12

    Dec

BA Boeing
$337.45

6.33 (1.91%)

10/21/19
STFL
10/21/19
UPGRADE
Target $24
STFL
Buy
JetBlue could be worth $28 in a takeout scenario, says Stifel
Stifel analyst Joseph DeNardi upgraded JetBlue to Buy from Hold with a price target of $24, up from $22. In a research note to investors, DeNardi says that a prolonged grounding of Boeing's (BA) 737 MAX is an "existential threat" to Southwest's (LUV) business model and that the "only reasonable option" Southwest has to address this risk is through an acquisition of JetBlue or Alaska Air (ALK). When combined with JetBlue's attractive CASMx story into 2020, the analyst now sees the increased likelihood of M&A as presenting a sufficiently attractive risk/reward setup to justify an upgrade. JetBlue could be worth $28 in a takeout scenario, DeNardi says. The Stifel analyst downgraded Southwest to Hold from Buy.
10/21/19
10/21/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Boeing (BA) downgraded to Neutral from Outperform at Credit Suisse and to Neutral from Buy at UBS. 2. Spirit AeroSystems (SPR) downgraded to Neutral from Buy at UBS with analyst Myles Walton citing Spirit's "outsized exposure" to Boeing's (BA) 737 Max program for the downgrade. 3. Gildan Activewear (GIL) downgraded to Hold from Buy at Edward Jones. 4. IBM (IBM) downgraded to Neutral from Buy at UBS with analyst Munjal Shah saying he believes it will be difficult for the company to achieve sustainable mid-single digit revenue growth. 5. Alcoa (AA) downgraded to Hold from Buy at Gabelli with analyst Justin Bergner saying Acloa's 12% two day post-earnings rally reflected better than expected proceeds from non-core asset sales and a view that estimates have bottomed. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/22/19
BUCK
10/22/19
NO CHANGE
Target $395
BUCK
Neutral
Buckingham no longer tactically bullish on Boeing amid continued negative news
Buckingham analyst Richard Safran continues to believe issues with Boeing's 737 MAX will be resolved and he sees a year end return to service for the aircraft. However, in light of continued negative news flow and increasingly negative investor sentiment, he has changed his view on the stock and is no longer tactically bullish. He keeps a Neutral rating and $395 price target on Boeing shares.
10/21/19
STFL
10/21/19
DOWNGRADE
Target $60
STFL
Hold
Stifel downgrades Southwest on risk of deal to lessen Boeing dependency
Stifel analyst Joseph DeNardi downgraded Southwest Airlines (LUV) to Hold from Buy with a price target of $60, down from $75. The stock in morning trading is up 7c to $53.55. Southwest is an all Boeing (BA) 737 airline, which makes its business model dependent on 737s, DeNardi tells investors in a research note. Southwest's decision to remove the 737 MAX from its schedule through early February, a "deteriorating" relationship between the Federal Aviation Administration and Boeing, and reports that Boeing may be looking at a 737 MAX rate cut indicate that Southwest "may be nearing a tipping point" where the duration of the MAX grounding pushes it to consider more significant and strategic solutions, including acquisitions, DeNardi contends. The analyst believes an acquisition by Southwest motivated by a desire to diversify away from the MAX "creates significant risks" in the near term for the company. DeNardi today also upgraded shares of JetBlue Airways (JBLU) to Buy from Hold.
TMO Thermo Fisher
$280.89

-2.56 (-0.90%)

10/16/19
CLVD
10/16/19
NO CHANGE
CLVD
Neutral
Thermo Fisher growth rate has moderated from first half, says Cleveland Research
Cleveland Research analyst Steve Willoughby said his recent checks suggest Thermo Fisher's growth rate has likely moderated from the first half of the year due to slower trends in Europe and China that are likely being somewhat offset by continued U.S. strength. He sees Q3 as "likely in-line" and thinks FY19 guidance appears realistic, though he said he is more concerned that the "end of year budget flush may be less impactful as compared to the past two years," Willoughby tells investors. He keeps a Neutral rating on Thermo Fisher shares.
07/16/19
07/16/19
DOWNGRADE
Target $315

Buy
Thermo Fisher downgraded to Buy at Needham on valuation, slower growth
As previously reported, Needham analyst Stephen Unger downgraded Thermo Fisher to Buy from Strong Buy with an unchanged price target of $315. The analyst cites the "meaningful valuation improvement" of 32% for the stock over the past six months vs. the 20% advance for S&P500 along with his expectation of decelerating near-term organic revenue growth from the 7.2% reported in Q1 given the slower global business investment spending environment.
07/16/19
NEED
07/16/19
DOWNGRADE
Target $315
NEED
Buy
Thermo Fisher downgraded to Buy from Strong Buy at Needham
Needham analyst Stephen Unger downgraded Thermo Fisher to Buy from Strong Buy with an unchanged price target of $315.
10/08/19
CLVD
10/08/19
NO CHANGE
CLVD
Cleveland sees 'noticeable' slowdown in Life Science equipment demand
Cleveland Research analyst Steve Willoughby says his recent research suggests a "noticeable slowing" in Life Science equipment demand during Q3 in Europe, China, and parts of the U.S. The analyst who adjusted estimates for Thermo Fisher (TMO), Waters (WAT), Agilent (A), Mettler-Toledo (MTD), Avantor (AVTR), PerkinElmer (PKI) and Bruker (BRKR), believes a broader industry slowdown could impact industry multiples which he notes have expanded so far this year.
BSX Boston Scientific
$38.21

-0.45 (-1.16%)

09/03/19
LEHM
09/03/19
INITIATION
Target $48
LEHM
Overweight
Boston Scientific reinstated with an Overweight at Barclays
Barclays analyst Kristen Stewart reinstated coverage of Boston Scientific with an Overweight rating and $48 price target. With multiple new products across all of its business units, the company is well positioned to sustain high-single digit organic sales growth for the foreseeable future, Stewart tells investors in a research note. She believes the consensus view on the stock "is the right view."
09/05/19
JPMS
09/05/19
INITIATION
Target $50
JPMS
Overweight
Boston Scientific reinstated with an Overweight at JPMorgan
JPMorgan analyst Robbie Marcus reinstated coverage of Boston Scientific with an Overweight rating and $50 price target following a period of restriction. The analyst continues to see the company as a "best-in-class Large-Cap MedTech asset," with "many shots on goal" to support a multi-year premium organic sales growth trajectory of 7%-10% through 2023.
09/05/19
09/05/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. General Electric (GE) initiated with an Equal Weight at Morgan Stanley. 2. Organigram (OGI) initiated with a Perform at Oppenheimer. 3. Wingstop (WING) initiated with a Market Perform at Raymond James. 4. Boston Scientific (BSX) reinstated with an Overweight at JPMorgan. 5. Cubic (CUB) initiated with a Hold at SunTrust. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/20/19
COWN
09/20/19
NO CHANGE
Target $47
COWN
Outperform
Boston Scientific setting up well for better second half, says Cowen
Cowen analyst Joshua Jennings said Boston Scientific is setting up for a batter second half to the year as the company has a steady flow of product launches scheduled for the second half and should also experience momentum in its core businesses over that interval. In addition, there is one more selling day in the second half versus one less in the first. Jennings reiterated his Outperform rating and $47 price target on Boston Scientific shares.
IVZ Invesco
$16.03

-0.115 (-0.71%)

10/22/19
EVER
10/22/19
DOWNGRADE
EVER
Underperform
UBS initiative to pressure retail asset managers like Invesco, says Evercore ISI
Evercore ISI analyst Glenn Schorr downgraded Invesco (IVZ) to Underperform from In Line after UBS (UBS) announced a unified initiative between its wealth management and asset management businesses to potentially revolutionize how clients access separately managed accounts including significantly reduced SMA pricing. In a research note to investors, Schorr says he thinks this could be an accelerant of price compression in retail asset management products. Schorr also downgraded Waddell & Reed (WDR) to Underperform.
10/22/19
EVER
10/22/19
DOWNGRADE
EVER
Underperform
Invesco downgraded to Underperform from In Line at Evercore ISI
Evercore ISI analyst Glenn Schorr downgraded Invesco to Underperform from In Line.
10/10/19
WELS
10/10/19
NO CHANGE
Target $17
WELS
Market Perform
Invesco price target lowered to $17 from $23 at Wells Fargo
Wells Fargo analyst Christopher Harris lowered his price target for Invesco to $17 from $23 given more conservative forecasts for fee rates and fund flows. The analyst reiterates a Market Perform rating on the shares.
10/22/19
EVER
10/22/19
DOWNGRADE
EVER
Underperform
Waddell & Reed downgraded at Evercore ISI after UBS announces new initiative
Evercore ISI analyst Glenn Schorr downgraded Waddell & Reed (WDR) to Underperform from In Line after UBS (UBS) announced a unified initiative between its wealth management and asset management businesses to potentially revolutionize how clients access separately managed accounts including significantly reduced SMA pricing. In a research note to investors, Schorr says he thinks this could be an accelerant of price compression in retail asset management products. Schorr also downgraded Invesco (IVZ) to Underperform.
LLY Eli Lilly
$110.00

2.06 (1.91%)

09/05/19
09/05/19
UPGRADE
Target $107

Outperform
Incyte upgraded to Outperform from Market Perform at JMP Securities
As previously reported, JMP Securities analyst Reni Benjamin assumed coverage of Incyte (INCY) with an upgraded rating of Outperform and a $107 price target. The analyst cites the "solid fundamentals" of the company's multi-billion dollar Jakafi franchise, including its recent approval in steroid refractory acute graft-versus-host disease, which he believes remains under-appreciated by investors. Benjamin is also positive on Incyte's "marquee" partners that include Novartis (NVS) and Eli Lilly (LLY), along with its $1.7B cash position, diverse pipeline, and strong fundamentals.
09/09/19
PIPR
09/09/19
NO CHANGE
Target $85
PIPR
Neutral
Lilly's 'impressive update' raised bar higher for Blueprint, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond said he thinks Eli Lilly (LLY) issued an "impressive update" on selpercatinib at the World Lung meeting, raising the bar for Blueprint Medicines' (BPMC) pralsetinib "meaningfully higher." While selpercatinib's "best-in-class" ORR was maintained, initial durability data could be upwards of 50% better than that of pralsetinib, according to Raymond. While cautioning that his comparison is highly preliminary, Raymond said he worries that LOXO-292's superiority gap against pralsetinib "may be widening." He keeps a Neutral rating on Blueprint shares, which are down about 3% in morning trading to $75.89.
09/25/19
PIPR
09/25/19
NO CHANGE
Target $81
PIPR
Overweight
AbbVie survey supports above-consensus estimates, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond keeps an Overweight rating on AbbVie (ABBV) shares with an $81 price target following a new rheumatologist survey by his firm's partners Spherix Global Insights. The survey indicates "robust" expectations for the company's oral JAK1 inhibitor Rinvoq, Raymond tells investors in a research note. Rheumatologists project that in six months, Rinvoq will leapfrog Eli Lilly's (LLY) Olumiant to become the second-most prescribed JAK with 5% share, says the analyst, citing the survey. He believes this supports his above-consensus Rinvoq revenue estimates.
10/16/19
BOFA
10/16/19
INITIATION
Target $133
BOFA
Buy
Eli Lilly reinstated with a Buy at BofA/Merrill
BofA/Merrill analyst Geoff Meacham reinstated coverage of Eli Lilly with a Buy rating and $133 price target. The analyst sees the company's "high quality, differentiated growth and modest expectations for added pipeline value" as compelling.
IRBT iRobot
$53.88

-1.82 (-3.27%)

10/09/19
10/09/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Domino's Pizza (DPZ) downgraded to Hold from Buy at Argus with analyst John Staszak citing its worse than expected Q3 revenue and earnings along with its new 2-3 year outlook of global retail sales growth of 7%-10% - down from its prior 3-5 year outlook of 8%-12% growth. 2. FedEx (FDX) downgraded to Market Perform from Outperform at Bernstein. 3. Waters (WAT) downgraded to Underweight from Equal Weight at Barclays with analyst Jack Meehan saying as leading indicators of the macro environment continue to weaken, he sees risk to the outlook for Waters' Industrial sales exposure. 4. iRobot (IRBT) downgraded to Underperform from Market Perform at Raymond James with analyst Brian Gesuale saying he thinks Street models aren't reflecting the beginning of a meaningful commoditization cycle across the RVC category. 5. Lincoln Electric (LECO) downgraded to Hold from Buy at Stifel with analyst Nathan Jones saying he still sees Lincoln Electric as "one of the highest quality businesses" in his coverage universe thanks to its strong management and leading technologies, but believes that the headwinds in the company's end market will limit the upside for investors in the near term. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/23/19
PIPR
10/23/19
NO CHANGE
Target $51
PIPR
Neutral
iRobot price target lowered to $51 from $64 at Piper Jaffray
Piper Jaffray analyst Troy Jensen lowered his price target for iRobot to $51 from $64 saying that while the company's Q3 results exceeded expectations, its initial outlook for Q4 and 2020 are "fairly dismal." The destruction in earnings is due to recent price increases related to tariff expenses, which are having a material impact on unit demand, especially at the high-end, Jensen tells investors in a research note. Until U.S. and China trade issues get resolved, iRobot will continue to struggle in its biggest market, "making it a hard stock to own," adds the analyst. Jensen lowered his estimates "meaningfully" and reiterates a Neutral rating on the shares.
10/16/19
SBSH
10/16/19
NO CHANGE
SBSH
Neutral
Citi opens negative catalyst watch on iRobot, citing Shark litigation
Citi analyst Asiya Merchant opened a negative catalyst watch on iRobot after the company filed a motion for a preliminary injunction against the Shark IQ Robot, claiming that SharkNinja infringed on three patents related to its Roomba i7+. The analyst noted that when iRobot previously won an exclusion order in December 2018 to bar Hoover and bobSweep products from being imported into the U.S., iRobot saw "a significant increase" in litigation expenses, to about $4.3B per year from $0.6B in the prior year. Merchant, who believes that the new Shark litigation could drive increased operating expenses for the company over the next few quarters, keeps a Neutral rating on iRobot shares.
10/16/19
JPMS
10/16/19
NO CHANGE
Target $69
JPMS
Neutral
iRobot price target lowered to $69 from $83 at JPMorgan
JPMorgan analyst Mark Strouse lowered his price target for iRobot (IRBT) to $69 from $83 and keeps a Neutral rating on the shares ahead of the company's Q3 results. The analyst expects "some quarter-to-quarter noise" in the second half of 2019 related to timing of Amazon (AMZN) orders, which he notes are expected to be unseasonably tilted towards Q4 owing to tariffs. In addition, initial reviews for the competing high-end Shark RVC are mostly positive, which may lead to share loss for iRobot during the key holiday season, Strouse tells investors in a pre-earnings research note. While iRobot has sued Shark for patent infringement, the analyst does not expect a decision prior to year-end, "meaning that holiday sales may still be at risk."
TXN Texas Instruments
$128.61

-2.32 (-1.77%)

10/23/19
JEFF
10/23/19
NO CHANGE
Target $150
JEFF
Buy
Texas Instruments selloff on outlook should be bought, says Jefferies
Jefferies analyst Mark Lipacis lowered his price target for Texas Instruments to $150 from $170 saying that while the reduced Q4 outlook surprised him, historical trend and inventory analyses "tell us the weakness should be bought." The last two times Texas Instruments sales spiked materially below the trendline were in 2009 and 2016, and 12 months later the shares outperformed the S&P 500 Index index by 27% and 37%, Lipacis tells investors in a research note. He keeps a Buy rating on the stock.
10/23/19
RHCO
10/23/19
NO CHANGE
Target $122
RHCO
Hold
Texas Instruments price target lowered to $122 from $133 at SunTrust
SunTrust analyst William Stein lowered his price target on Texas Instruments to $122 and kept his Hold rating after its "weak but not surprising" Q3 results. The analyst notes that the quarter suggests that industry fundamentals will not bottom until Q4, stating that the guidance for next quarter was "especially surprising" and reflects further deceleration in sales while pushing the bottom of the cycle timing by one quarter. Stein adds that all of the company's end markets saw weakness, but Communications was "particularly bad", falling 20% from last quarter and 35% from last year.
10/23/19
RBCM
10/23/19
NO CHANGE
Target $124
RBCM
Sector Perform
Texas Instruments price target lowered to $124 from $134 at RBC Capital
RBC Capital analyst Mitch Steves lowered his price target on Texas Instruments to $124 and kept his Sector Perform rating after its Q3 revenues came in a "tad below" expectations and Q4 guidance also missed forecasts. The analyst notes that the broad-based weakness in semiconductors remains evident, even though he sees the company as "one of the best-in-class" assets over the 5-10 year time frame. Steves adds that the valuation on Texas Instruments appears "full".
10/23/19
OPCO
10/23/19
NO CHANGE
Target $120
OPCO
Outperform
Texas Instruments price target lowered to $120 from $140 at Oppenheimer
Oppenheimer analyst Rick Schafer lowered his price target for Texas Instruments to $120 from $140 following quarterly results. The analyst reiterates an Outperform rating on the shares.
TNK Teekay Tankers
$1.99

0.08 (4.19%)

10/18/19
EVER
10/18/19
UPGRADE
EVER
Outperform
Frontline, Nordic American Tankers upgraded at Evercore ISI
As previously reported, Evercore ISI analyst Jonathan Chappell upgraded Frontline (FRO) to Outperform from In Line with a $14 price target and upgraded Nordic American Tankers (NAT) to In Line from Underperform. The "eye-watering" spot rates that "turbo-charged" have already pulled back, but are settling above not only pre-spike levels and year-to-date averages, but also ahead of "many of the most bullish estimates on the Street," Chappell tells investors. Fundamental and IMO 2020 improvements are combining to reset the base case for oil tankers just as favorable seasonal factors set in, contends Chappell, who names Euronav NV (EURN), Scorpio Tankers (STNG) and Teekay Tankers (TNK) as his top tanker picks.
10/23/19
JEFF
10/23/19
UPGRADE
Target $2.5
JEFF
Buy
Teekay Tankers upgraded to Buy from Hold at Jefferies
Jefferies analyst Randy Giveans upgraded Teekay Tankers to Buy from Hold with a $2.50 price target.
10/23/19
JEFF
10/23/19
UPGRADE
Target $2.5
JEFF
Buy
Jefferies upgrades Teekay Tankers to Buy, boosts target to $2.50 from $1.50
Jefferies analyst Randy Giveans upgraded Teekay Tankers to Buy from Hold with a price target of $2.50, up from $1.50. The analyst increased his price targets for all tanker companies saying asset values are starting to reflect the "massive increases" in charter rates. Teekay Tankers had the largest price target increase on a percentage basis. The analyst expects OPEC production surprises to the upside to cause crude oil tanker demand and correspondingly crude oil tanker charter rates and asset values to strengthen.
10/02/19
10/02/19
NO CHANGE

Teekay Corp. Investor Day has been postponed
The Investor Day that was to be held in New York on October 2 at 8 am has been postponed.
REZI Resideo
$15.17

0.03 (0.20%)

10/23/19
OPCO
10/23/19
DOWNGRADE
OPCO
Perform
Resideo downgraded to Perform from Outperform at Oppenheimer
03/12/19
03/12/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Snap (SNAP) initiated with an Overweight at Consumer Edge. 2. Crinetics (CRNX) initiated with an Overweight at Cantor Fitzgerald. 3. Tellurian (TELL) initiated with a Buy at BTIG. 4. Stealth Biotherapeutics (MITO) initiated with an Outperform at Evercore ISI, a Buy at Nomura Instinet, and a Hold at Jefferies. 5. Resideo (REZI) initiated with an Outperform at Imperial Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/23/19
OPCO
10/23/19
DOWNGRADE
OPCO
Perform
Resideo downgraded to Perform on revised guidance at Oppenheimer
As previously reported, Oppenheimer analyst Ian Zaffino downgraded Resideo to Perform from Outperform after the company, once again, revised guidance negatively. This time, the company pre-announced Q3 and lowered fiscal year 2019 guidance, based on a slowdown in the RTS gas combustion business and an unfavorable change-over in thermostats, he notes.
08/13/19
OPCO
08/13/19
NO CHANGE
Target $20
OPCO
Outperform
Resideo price target lowered to $20 from $30 at Oppenheimer
Oppenheimer analyst Ian Zaffino lowered his price target for Resideo to $20 from $30 as he is concerned with the company's margin profile over the next 2-3 years. The analyst believes Resideo could face a permanently lower margin profile in security, as well as increased investment spend and near-term headwinds created by its transition from high-margin, non-connected devices to lower-margin, connected devices. Zaffino has an Outperform rating on the shares.
NOW ServiceNow
$228.26

-12.315 (-5.12%)

10/23/19
UBSW
10/23/19
NO CHANGE
Target $232
UBSW
Buy
ServiceNow stock price attractive following aftermarket decline, says UBS
UBS analyst Jennifer Lowe is keeping her Buy rating and $232 price target on ServiceNow (NOW) after the stock fell afterhours yesterday on the news that its CEO John Donahoe is leaving for a CEO post at Nike (NKE). The analyst notes that the company also pre-announced Q3 ahead of consensus while its FY19 outlook indicates no change to Q4 guidance. Lowe adds that although ServiceNow is faced with new CEO transition risk, the former SAP CEO Bill McDermott is also "seasoned", and the stock is "attractive" at a 29-times enterprise value to expected 2020 free cash flow.
10/23/19
JEFF
10/23/19
NO CHANGE
Target $330
JEFF
Buy
ServiceNow shares may remain range-bound, says Jefferies
While ServiceNow's preliminary Q3 results beat subscriber billings expectations, the implied Q4 subscription revenue and billings guidance were both below consensus, Jefferies analyst Samad Samana tells investors in a research note. The analyst is not sure the Q3 results will be enough to drive shares higher in the near-term given the implied Q4 guidance, the uncertainty created by ServiceNow's leadership changes, and concerns facing high-growth software. However, he sees Bill McDermott as a "solid" CEO hire given his "successful track record in enterprise software." Samana keeps a Buy rating on ServiceNow shares with a $330 price target.
10/23/19
COWN
10/23/19
NO CHANGE
Target $315
COWN
Outperform
ServiceNow new CEO well-suited for next growth phase, says Cowen
Cowen analyst J. Derrick Wood noted ServiceNow (NOW) announced its CEO would be leaving to be CEO of Nike (NKE) and that ex-SAP (SAP) CEO Bill McDermott will take his place. The company also preannounced its Q3 results, beating estimates on billings growth and raising guidance on the high-end. The analyst noted the CEO change was a surprise but he believes McDermott's skill set should be well-suited for the company's next growth phase. Wood reiterated his Outperform rating and $315 price target on ServiceNow shares.
10/23/19
MACQ
10/23/19
NO CHANGE
Target $243
MACQ
Outperform
Macquarie a buyer of ServiceNow, says Bill McDermott a 'huge win'
Macquarie analyst Sarah Hindlian says that while she understands the uncertainty in ServiceNow shares around the departure of John Donahoe and the lack of a CFO appointment, she thinks the preliminary results "spoke volumes against the bear case." Further, the analyst sees incoming CEO Bill McDermott "as one of the best executives available in enterprise software." McDermott is a "huge win," contends Hindlian, who is a buyer of ServiceNow shares into today's conference call. She has a Buy rating on the stock with a $335 price target.
MGNX MacroGenics
$11.04

-0.34 (-2.99%)

10/23/19
LEER
10/23/19
NO CHANGE
Target $18
LEER
Outperform
MacroGenics price target lowered to $18 from $26 at SVB Leerink
SVB Leerink analyst Jonathan Chang lowered his price target for $18 from $26 after the company announced data from the second interim overall survival analysis of the Phase III SOPHIA study of margetuximab in HER2+ metastatic breast cancer. While the analyst does not have the complete picture based on the top-line data disclosed in the press release, he is conservatively lowering his estimates based on his concern that any improvement in the data may only be incremental and in the context of a highly competitive and evolving breast cancer landscape. Chang reiterates an Outperform rating on the shares.
06/05/19
STFL
06/05/19
NO CHANGE
Target $29
STFL
Buy
MacroGenics price target lowered to $29 from $36 at Stifel
Stephen analyst Kevin Willey lowered his price target for MacroGenics to $29 from $36, saying he expects maturing overall survival data from Sophia to command "meaningful" regulatory and commercial importance given what is likely to remain perceived to be a progression free survival benefit of uncertain clinical relevance. Willey tells investors in a research note that he is now less optimistic directionally-supportive OS data will manifest over time in the intent-to-treat patient population and has "minimal" confidence the early numerical OS separation favoring margetuximab in CD16A-158F patients will prove durable. He maintains a Buy rating.
07/18/19
HCWC
07/18/19
NO CHANGE
Target $39
HCWC
Buy
H.C. Wainwright sees 'nothing sinister' with MacroGenics regaining drug rights
H.C. Wainwright analyst Debjit Chattopadhyay sees nothing "inherently sinister" with flotetuzumab after MacroGenics regained the full rights to the drug. After speaking with management, the analyst says that ex-partner Servier was not been particularly engaged during the development process and that to date, MacroGenics has been funding both the U.S. and European studies. Further, flotetuzumab's emerging clinical profile remains consistent with what was presented at ASH 2018, and an updated presentation on the fully enrolled dose expansion cohort is expected at ASH 2019, Chattopadhyay tells investors in a research note. He keeps a Buy rating on MacroGenics shares with a $39 price target.
10/23/19
WEDB
10/23/19
NO CHANGE
Target $14
WEDB
Outperform
MacroGenics price target lowered to $14 from $23 at Wedbush
Wedbush analyst David Nierengarten lowered his price target for MacroGenics to $14 from $23 following a worse-than-expected readout of the second interim OS analysis, prompted at 270 events, from the pivotal Phase 3 SOPHIA trial evaluating margetuximab and chemo against trastuzumab and chemo in patients with 3/4L HER2+ metastatic breast cancer. The analyst believes that "perhaps the most concerning read from the update" is the deterioration of margetuximab's relative benefit over trastuzumab in the CD16A 158F allele population, which saw a relative OS benefit of 6.7 months at the first interim analysis drop to 4.3 months at the second, largely due to better-than-expected survival in the trastuzumab arm. Nierengarten has an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

CPG

Crescent Point Energy

$3.96

0.035 (0.89%)

17:02
11/14/19
11/14
17:02
11/14/19
17:02
Hot Stocks
Crescent Point Energy to sell Sasketchewan gas infrastructure assets for $500M »

Crescent Point Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VVV

Valvoline

$23.05

0.035 (0.15%)

17:00
11/14/19
11/14
17:00
11/14/19
17:00
Hot Stocks
Valvoline raises quarterly dividend 7% to 11.3c per share »

Valvoline announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

SYY

Sysco

$81.51

0.27 (0.33%)

17:00
11/14/19
11/14
17:00
11/14/19
17:00
Hot Stocks
Sysco raises quarterly diviend to 45c from 39c per share »

The new dividend is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

NGVC

Natural Grocers

$9.28

0.64 (7.41%)

16:57
11/14/19
11/14
16:57
11/14/19
16:57
Hot Stocks
Natural Grocers issues recall on organic soybeans due to mold »

Cottage Natural Food…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

KMPH

KemPharm

$0.51

0.0229 (4.66%)

16:56
11/14/19
11/14
16:56
11/14/19
16:56
Earnings
KemPharm reports Q3 diluted EPS 6c, consensus (19c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

MTD

Mettler-Toledo

$713.22

-8.48 (-1.18%)

16:55
11/14/19
11/14
16:55
11/14/19
16:55
Initiation
Mettler-Toledo initiated  »

Mettler-Toledo initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WAT

Waters

$213.34

-0.06 (-0.03%)

16:52
11/14/19
11/14
16:52
11/14/19
16:52
Initiation
Waters initiated  »

Waters initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NBSE

NeuBase Therapeutics

$5.19

0.04 (0.78%)

, HGV

Hilton Grand Vacations

$35.29

0.05 (0.14%)

16:51
11/14/19
11/14
16:51
11/14/19
16:51
Hot Stocks
Greenlight raises stake in Brighthouse, cuts stake in Dillard's »

David Einhorn's…

NBSE

NeuBase Therapeutics

$5.19

0.04 (0.78%)

HGV

Hilton Grand Vacations

$35.29

0.05 (0.14%)

KAR

KAR Auction

$22.80

0.88 (4.01%)

VAL

Valaris

$4.09

-0.25 (-5.76%)

CARS

Cars.com

$12.56

0.48 (3.97%)

BHF

Brighthouse Financial

$40.06

0.055 (0.14%)

CC

Chemours

$18.54

0.2 (1.09%)

GM

General Motors

$36.80

-0.4 (-1.08%)

ADNT

Adient

$20.37

-0.705 (-3.35%)

DDS

Dillard's

$77.04

9.235 (13.62%)

GRBK

Green Brick

$11.69

0.03 (0.26%)

AER

AerCap

$59.97

-0.39 (-0.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

BGNE

BeiGene

$195.90

-1.25 (-0.63%)

16:50
11/14/19
11/14
16:50
11/14/19
16:50
Hot Stocks
Breaking Hot Stocks news story on BeiGene 

BeiGene trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 27

    Feb

PAYS

Paysign

$11.27

-0.56 (-4.73%)

16:47
11/14/19
11/14
16:47
11/14/19
16:47
Initiation
Paysign initiated  »

Paysign initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AWK

American Water

$117.90

0.945 (0.81%)

16:47
11/14/19
11/14
16:47
11/14/19
16:47
Hot Stocks
Pennsylvania American Water to acquire Kane Authority wastewater assets »

Pennsylvania American…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AVTR

Avantor

$15.98

0.36 (2.30%)

16:46
11/14/19
11/14
16:46
11/14/19
16:46
Initiation
Avantor initiated  »

Avantor initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EUSHF

Eurocash

$0.00

(0.00%)

16:46
11/14/19
11/14
16:46
11/14/19
16:46
Downgrade
Eurocash rating change  »

Eurocash downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:45
11/14/19
11/14
16:45
11/14/19
16:45
General news
Breaking General news story  »

Dallas Federal Reserve…

16:45
11/14/19
11/14
16:45
11/14/19
16:45
General news
Breaking General news story  »

Dallas Federal Reserve…

TMO

Thermo Fisher

$300.82

0.92 (0.31%)

16:44
11/14/19
11/14
16:44
11/14/19
16:44
Initiation
Thermo Fisher initiated  »

Thermo Fisher initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 07

    Dec

RH

RH

$175.19

1.98 (1.14%)

16:41
11/14/19
11/14
16:41
11/14/19
16:41
Hot Stocks
Breaking Hot Stocks news story on RH »

RH jumps 6% to $186.56…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PTON

Peloton

$25.96

0.015 (0.06%)

, ALC

Alcon

$58.90

-0.17 (-0.29%)

16:41
11/14/19
11/14
16:41
11/14/19
16:41
Hot Stocks
Soros adds to Celgene position, lowers Caesars stake, exits Disney »

George Soros' Soros…

PTON

Peloton

$25.96

0.015 (0.06%)

ALC

Alcon

$58.90

-0.17 (-0.29%)

ALLY

Ally Financial

$30.83

0.15 (0.49%)

ORCC

Owl Rock

$18.20

0.2 (1.11%)

DIS

Disney

$147.19

-1.5 (-1.01%)

VMC

Vulcan Materials

$141.66

3.04 (2.19%)

CAG

Conagra Brands

$28.45

0.13 (0.46%)

CELG

Celgene

$110.03

-0.42 (-0.38%)

EPC

Edgewell Personal Care

$31.40

-0.815 (-2.53%)

VST

Vistra Energy

$26.34

0.34 (1.31%)

NLY

Annaly Capital

$9.11

0.035 (0.39%)

C

Citi

$73.85

-0.06 (-0.08%)

CZR

Caesars

$12.86

0.09 (0.70%)

VICI

VICI Properties

$24.58

0.24 (0.99%)

MS

Morgan Stanley

$48.61

0.22 (0.45%)

ADM

Archer Daniels

$42.78

-0.04 (-0.09%)

LBRDK

Liberty Broadband

$119.07

0.36 (0.30%)

GOOGL

Alphabet Class A

$1,309.61

13.61 (1.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 14

    Nov

  • 14

    Nov

  • 15

    Nov

  • 19

    Nov

  • 20

    Nov

  • 21

    Nov

  • 02

    Dec

  • 04

    Dec

  • 06

    Dec

  • 07

    Dec

  • 09

    Dec

  • 14

    Jan

  • 25

    Mar

  • 04

    Apr

RH

RH

$175.19

1.98 (1.14%)

, OXY

Occidental Petroleum

$37.76

-0.36 (-0.94%)

16:40
11/14/19
11/14
16:40
11/14/19
16:40
Hot Stocks
Breaking Hot Stocks news story on RH, Occidental Petroleum »

Buffett's Berkshire…

RH

RH

$175.19

1.98 (1.14%)

OXY

Occidental Petroleum

$37.76

-0.36 (-0.94%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:39
11/14/19
11/14
16:39
11/14/19
16:39
General news
Fed Balance Sheet Level data reported »

Week of 11/13 Fed Balance…

QGEN

Qiagen

$37.31

1.785 (5.03%)

16:38
11/14/19
11/14
16:38
11/14/19
16:38
Initiation
Qiagen initiated  »

Qiagen initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

ILMN

Illumina

$298.43

0.32 (0.11%)

16:36
11/14/19
11/14
16:36
11/14/19
16:36
Initiation
Illumina initiated  »

Illumina initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REDU

Rise Education

$7.42

-0.24 (-3.13%)

16:35
11/14/19
11/14
16:35
11/14/19
16:35
Earnings
Rise Education reports Q3 Net income RMB 39.6M, up 22.4% from last year »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

16:35
11/14/19
11/14
16:35
11/14/19
16:35
General news
Money Supply M2 Weekly Change data reported »

Week of 11/4 Money Supply…

RGEN

Repligen

$81.70

-1.45 (-1.74%)

16:34
11/14/19
11/14
16:34
11/14/19
16:34
Initiation
Repligen initiated  »

Repligen initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.